Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 2, 2009, Pages 213-217

  Cahn, Pedro ^a   Wainberg, Mark A ^b  

^a FUNDACIÓN HUÉSPED   (Argentina)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Antiretroviral drugs; Drug resistance; HIV

Indexed keywords

ABACAVIR; APRICITABINE; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; CLINICAL TRIAL; CODON; CROSS RESISTANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG STRUCTURE; GENE INSERTION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; PROTEIN PHOSPHORYLATION; REVIEW; VIRUS LOAD; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 77950255107     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp422     Document Type: Review

References (22)

1. de Muys J-M, Gourdeau H, Nguyen-Ba N et al. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine.Antimicrob Agents Chemother 1999; 43: 1835-44.
2. Taylor DL, Ahmed PS, Tyms AS et al. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(±)-2′-deoxy-3′-oxa-4′-thiocytidine, dOTC]. Antivir Chem Chemother 2000; 11: 291-301.
3. Bethell RC, Lie YS, Parkin NT. In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antivir Chem Chemother 2005; 16: 295-302.
4. Gu Z, Allard B, de Muys JM et al. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob Agents Chemother 2006; 50: 625-31.
5. Cox S, Parkin N, Limoli K et al. Antiviral activity of ATC in vitro against HIV isolates with combinations of NRTI resistance mutations. In: Abstracts of the Eleventh European AIDS Conference, Madrid, Spain, 2007 http://www.abstractserver.com/eacs2007/oaa/documents/P7.1-02_1.pdf Abstract P7.1/02 (19 October 2009, date last accessed)
6. Gu Z, Nguyen-Ba N, Ren C et al. BCH-10618, a new heterosubstituted nucleoside analogue against HIV-1 infection. Antivir Ther 2001; 6 Suppl 1: 8.
7. Frankel FA, Coutsinos D, Xu H et al. Kinetics of inhibition of HIV type 1 reverse transcriptase-bearing NRTI-associated mutations by apricitabine triphosphate. Antivir Chem Chemother 2007; 18: 93-101.
8. Southby J, Limoli K, Goss J et al. Effect of mutations at codon 69 of HIV-1 reverse transcriptase on susceptibility to apricitabine and other nucleoside reverse transcriptase inhibitors. Antivir Ther 2009; 14 Suppl 1: A139.
9. Ntemgwa M, Wainberg MA, Oliveira M et al. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob Agents Chemother 2007; 51: 3861-9.
10. Delviks-Frankenberry KA, Nikolenko GN, Barr R et al. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3′-azido-3′-deoxythymidine resistance. J Virol 2007; 81: 6837-45.
11. Oliveira M, Moisi D, Spira B et al. Apricitabine does not select additional drug resistance mutations in tissue culture in HIV-1 variants containing K65R, M184V or M184V plus thymidine analogue mutations. Antimicrob Agents Chemother 2009; 53: 1683-5.
12. Cahn P, Altclas J, Martins M et al. Superior activity of apricitabine compared to 3TC over 21 days in treatment experienced HIV-1 infected patients failing therapy with M184V and NRTI resistance. In: Abstracts of the Fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, 2007. Abstract WESS203. http://wwwias2007.org/pag/Abstracts.aspx?SID=151&AID=5474 (19 October 2009, date last accessed).
13. Cahn P, Altclas J, Martins M et al. 24 Week data from study AVX-201: a prospective, randomised, double-blind, dose-ranging phase 2b study of apricitabine in treatment-experienced patients with M184V and NRTI resistance. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2008. Abstract 793 http://www.retroconference.org/2008/Abstracts/31004.htm (19 October 2009, date last accessed).
14. Cahn P, Altclas J, Martins M et al. 48-Week data from Study AVX-201-a randomised phase 2b study of apricitabine in treatment-experienced patients with M184V and NRTI resistance. In: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK, 2008. Abstract 0414. http://www.jiasociety.org/content/pdf/1758-2652-11-S1-O41.pdf (19 October 2009, date last accessed).
15. Cahn P, Cassetti I, Wood R et al. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. AIDS 2006; 20: 1261-8.
16. Cox S, Southby J, Moore S. Genotypic analysis of patients enrolled in Study AVX-201 and treated with apricitabine for 24 weeks. Antivir Ther 2008; 13 Suppl 3: A22.
17. Petrella M, Wainberg WA. Might the M184V substitution in HIV-1 RT confer clinical benefit? AIDS Rev 2002; 4: 224-32.
18. Miller MD, Margot NA, Hertogs K et al. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids 2001; 20: 1025-8.
19. Cox S, Southby J. Apricitabine-a novel nucleoside reverse transcriptase inhibitor for the treatment of HIV infection that is refractory to existing drugs. Expert Opin Investig Drugs 2009; 18: 199-209.
20. Bethell R, de Muys J, Lippens J et al. In vitro interactions between apricitabine and other deoxycytidine analogues. Antimicrob Agents Chemother 2007; 51: 2948-53.
21. Holdich T, Shiveley LA, Sawyer J. Effect of lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2007; 51: 2943-7.
22. Sarafianos SG, Das K, Clark AD et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with b-branched amino acids. Proc Natl Acad Sci USA 1999; 96: 10027-32.